Following the turmoil of the global pandemic, and the current economic climate the pharmaceutical industry has had to find new ways to respond to the needs of healthcare. One such company is Kent Athlone Pharma Group, so we wanted to interview its CEO, Terry Petersen, to find out more.
To begin, please could you give us an overview of Kent Athlone Pharma Group?
Kent Athlone Pharma Group is a Specialty, European Pharmaceutical Company with offices and production sites in the UK and Ireland. The company has a broad portfolio of Value-Added Medicines, and for example is already one of the largest suppliers of Hospital Injectables, and antibiotics to the NHS, in the UK.
Likewise, we have a very successful service business within the Group, which provides a valuable service to NHS organisations as one of the leading providers of over-labelling services in the UK.
The company has a long heritage dating back to 1986, supporting/collaborating with customers in the UK, Ireland, and Internationally through a network of partners across Europe, and around the globe.
Could you tell us more about how you started with Kent Athlone Pharma Group, and how your past experience guided you to making such a difference to the team?
I joined the company as CEO, in July 2022, to work with an established, & experienced team, to help lead, and facilitate the ongoing rapid growth of the business, as we seek to service our customers and support patients in the UK, Europe, and beyond.
In terms of my professional background, I have spent the last 20+ years shaping and leading pharmaceutical businesses in Europe (Largely for Global Multi-Nationals), and I was very pleased to join Kent Athlone Pharma Group, because I could see the future potential to grow the business, with an excellent current portfolio of products, a strong product pipeline, and a committed team.
How do you approach your business strategy?
On joining the company 12 months ago, we took the time to speak/meet with every single employee, to understand their perspective in terms of what was working and what we needed to focus on improving. We identified a number of key areas including company culture, product portfolio, medium-term Company Strategy, and operational excellence.
We also spent time analysing our business, and our company processes to identify where we really needed to focus, to transition the business from a “Good” to a “Great” Company in the next few years.
What challenges have you faced, or think you will face, due to the nature of your industry?
Like any company in the recent economic climate, we have had to manage a number of challenges on an ongoing basis. For example, we face the ongoing challenges of global medicine shortages, substantial increases in cost of goods, and the low margins for some Value-Added Medicines in many countries.
And of course, it is taken as a given that we will operate at all times with the appropriate levels of compliance in line with our regulatory obligations, and our Corporate Social Responsibility as a manufacturer and employer in the UK and Ireland.
What do you value in your team and how does Kent Athlone Pharma Group cultivate a rich environment for personal and professional growth?
Over the last 12 months, one thing that has always impressed me, has been the level of commitment from our team, the desire to get it right for our customers every day, and the level of collaboration across every function across the business. We have a great team which I am very proud of.
Within Kent Athlone Pharma Group, we call this the “One Team” culture, and it is something we have really focussed on and invested in bringing to life in everything that we do.
We have taken the time to re-define our company values, and they guide our approach in everything that we do: Honesty, Teamwork, Diversity, Commitment, Agility, and Leadership.
When we are recruiting in addition to the right experience, we also think very carefully about if the cultural fit is there for both parties. This is a fast-moving, action-orientated, hands-on culture where “smart, goal-orientated, precise, driven, do’ers” thrive. It is not for the faint-hearted, but it is a stimulating environment for the right people, who enjoy learning/collaborating, where individuals are provided with genuine autonomy to drive the business forwards and take pride in making a difference every day.
We proactively invest in frequent and engaging communication/events with the whole team, so everyone is kept informed, all of the time, and has the opportunity to share their views openly, make suggestions for improvement and ask questions freely.
The biggest investment that we make every year as a business is in our people.
To finish, what are your plans for the future?
Our 5-year growth strategy is focussed on five pillars:
- Expand the Product Portfolio: Through pro-active Business Development, Partnering and New Product Development. Our focus going forwards will be differentiated Value Added Medicines, in 5 core therapy areas: Anti-Infectives, Pain, Ophthalmology, Oncology, Hospital Injectables.
- Effectively launch and commercialise: Working closely with our partners, and regulatory bodies to launch products on time, and then effectively promoting/distributing these products to achieve commercial expectations.
- Expand the presence Internationally: Of our product range either via direct distribution or partnering.
- Improve Operational Excellence: Effectively managing our supply chain, and business functions via streamlined, integrated and automated applications, systems and processes.
- Build and maintain a High Performance Culture: That attracts, retains, develops and engages a high calibre, diverse team.
In summary the future outlook for Kent Athlone Pharma Group looks strong. We have a clear Growth Strategy, a Great Team a positive Company Culture, and the ambition to do everything we can to get it right for our customers, partners and the patients we serve, every day.
We appreciate hearing from Terry as he secures the title of Most Influential Pharmaceutical Products Development & Supply CEO 2023 – UK from CEO Monthly.
For further information, please contact Terry Peterson or visit https://www.kentpharm.co.uk/
